---
title: "Acrivon ends Akoya companion diagnostic agreement"
url: "https://aibio.space/news/acrivon-ends-akoya-companion-diagnostic-agreement-takes-testing-house/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-03-02"
section: "Distress"
tickers: "NASDAQ:ACRV"
source: "https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/d111455d8k.htm"
summary: "The February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test."
---

By the aibio.space news desk.

Sources

- [Acrivon Therapeutics, Inc. 8-K (2026-03-02)](https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/d111455d8k.htm)

[ACRV](https://aibio.space/companies/acrivon-therapeutics/)

2026-03-02

# Acrivon ends Akoya companion diagnostic agreement and takes testing in-house

Tickers [ACRV](https://aibio.space/companies/acrivon-therapeutics/)

The February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test.

## Key facts

- **Company**: Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

- **News type**: Distress

- **Primary source**: [Acrivon Therapeutics, Inc. 8-K (2026-03-02)](https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/d111455d8k.htm)

*A supreme court building with lit columns. CC0, via rawpixel. The picture shows the field, not the companies named.*

Acrivon Therapeutics, Inc. ([ACRV](https://aibio.space/companies/acrivon-therapeutics/)) and Akoya Biosciences, a wholly owned subsidiary of Quanterix Corporation, signed a Termination and Transition Agreement on February 25, 2026. It ends the OncoSignature Companion Diagnostic Agreement dated June 17, 2022. The filing says the termination involves no financial payments from or to any party.

Acrivon announced on February 18, 2026 that it had completed and certified its own CLIA laboratory in Watertown, Massachusetts. With that in-house capability, it will move ACR-368 OncoSignature testing to the new lab. Quanterix and Acrivon agreed to a transition plan to transfer the procedures, materials and know-how from Akoya's earlier testing and development work to Acrivon.

During the transfer, Quanterix is expected to keep meeting all ACR-368 OncoSignature clinical testing requirements for Acrivon's ongoing registrational-intent Phase 2b study.

Acrivon says that, as part of the termination, it has ensured full development and commercialization rights to its proprietary ACR-368 OncoSignature test. The company believes in-house operations give it more control over biomarker identification and companion diagnostic development.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ACRV

Acrivon Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/acrivon-ends-akoya-companion-diagnostic-agreement-takes-testing-house/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Acrivon ends Akoya companion diagnostic agreement", 2026-03-02, https://aibio.space/news/acrivon-ends-akoya-companion-diagnostic-agreement-takes-testing-house/